Home › NDC Lookup › RxCUI directory › RxCUI 1551885

Lanthanum carbonate 750 MG Oral Powder — RxCUI 1551885

RxNorm drug concept · Semantic clinical drug
RxCUI 1551885 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1551885
Official nameLanthanum carbonate 750 MG Oral Powder
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped5
Package NDCs mapped5
Reported Medicaid activity (SDUD)41 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Lanthanum carbonate 750 MG Oral Powder Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lanthanum carbonate 750 MG Oral Powder RxCUI 1551885

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lanthanum carbonate 234416
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Fosrenol 356761
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lanthanum carbonate Oral Powder 1551880
    • Lanthanum carbonate Oral Powder Product 1551879
    • Lanthanum carbonate Oral Product 1162547
    • Lanthanum carbonate Oral Powder [Fosrenol] 1551882
    • Fosrenol Oral Powder Product 1551883
    • Fosrenol Oral Product 1173292
    • Oral Powder 346289
    • Oral Powder Product 1294711
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lanthanum carbonate 750 MG SCDC · 602636
  • Lanthanum carbonate Oral Powder SCDF · 1551880
  • Lanthanum carbonate Oral Powder Product SCDG · 1551879
  • Lanthanum carbonate Oral Product SCDG · 1162547

Brand-Name Concepts

  • Lanthanum carbonate 750 MG Oral Powder [Fosrenol] SBD · 1551886
  • Lanthanum carbonate 750 MG [Fosrenol] SBDC · 603121
  • Lanthanum carbonate Oral Powder [Fosrenol] SBDF · 1551882
  • Fosrenol Oral Powder Product SBDG · 1551883
  • Fosrenol Oral Product SBDG · 1173292
  • Fosrenol BN · 356761

📦 FDA Products & Package NDCs

5 products · 5 package NDCs
5 package NDCs map to RxCUI 1551885 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
54092-0252-90 2 BOTTLE in 1 PACKAGE (54092-252-90) / 45 TABLET, CHEWABLE... Fosrenol Takeda Pharmaceuticals America, Inc. 2004-10-26
54092-0253-90 6 BOTTLE in 1 PACKAGE (54092-253-90) / 15 TABLET, CHEWABLE... Fosrenol Takeda Pharmaceuticals America, Inc. 2005-11-23
54092-0254-90 9 BOTTLE in 1 PACKAGE (54092-254-90) / 10 TABLET, CHEWABLE... Fosrenol Takeda Pharmaceuticals America, Inc. 2005-11-23
54092-0256-02 9 CARTON in 1 PACKAGE (54092-256-02) / 10 POWDER in 1 CARTO... Fosrenol Takeda Pharmaceuticals America, Inc. 2014-09-24
54092-0257-02 9 CARTON in 1 CARTON (54092-257-02) / 10 POWDER in 1 CARTON... Fosrenol Takeda Pharmaceuticals America, Inc. 2014-09-24
Observed labelers: Takeda Pharmaceuticals America, Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.